Arexvy (respiratory syncytial virus vaccine, adjuvanted) – New vaccine approval
May 3, 2023 - The FDA announced the approval of GSK’s Arexvy (respiratory syncytial virus vaccine, adjuvanted), for active immunization for the prevention of lower respiratory tract disease (LRTD) caused by respiratory syncytial virus (RSV) in individuals 60 years of age and older.
Top